Becton, Dickinson and Company's Q3 2025 Earnings Preview: Analyst Expectations and Stock Performance

Becton Dickinson and Company (BDX) is expected to report Q3 2025 earnings before the market opens on Aug. 7. Analysts expect a profit of $3.42 per share, down 2.3% from the year-ago quarter. For the full year, analysts expect EPS of $14.17, up 7.8% from fiscal 2024. BDX stock has underperformed the S&P 500 Index over the past 52 weeks, down 22.6%. Analysts have a "Moderate Buy" rating with an average price target of $213.71, indicating a potential upside of 16.4% from current levels.

Becton Dickinson and Company (BDX), a global leader in medical technology, is set to release its fiscal third-quarter earnings for 2025 before the market opens on Thursday, Aug. 7. Analysts expect the company to report a profit of $3.42 per share on a diluted basis, a 2.3% decrease from the $3.50 per share achieved in the year-ago quarter [1].

For the full year, analysts predict BDX's earnings per share (EPS) to be $14.17, representing a 7.8% increase from the $13.14 recorded in fiscal 2024. This growth is expected to continue, with EPS projected to rise by 3.4% year over year to $14.65 in fiscal 2026 [1].

Despite these positive expectations, BDX stock has significantly underperformed the S&P 500 Index over the past 52 weeks, with shares down 22.6% compared to the index's 17.3% gain. The company's underperformance can be attributed to a software recall in its Alaris infusion pump systems, which has posed risks to patient safety [1].

Analysts' consensus on BDX stock is bullish, with a "Moderate Buy" rating and an average price target of $213.71, indicating a potential upside of 16.4% from current levels. This rating is supported by seven "Strong Buy" ratings, one "Moderate Buy," and nine "Hold" ratings from analysts covering the stock [1].

Institutional investors have also shown confidence in BDX, with several notable increases in holdings. John G. Ullman & Associates Inc. raised its holdings by 11.8% during the first quarter, and T. Rowe Price Investment Management Inc. increased its stake by 36.1% in the fourth quarter [2]. These investments suggest that analysts and institutional investors are optimistic about BDX's long-term prospects.

Becton Dickinson and Company's upcoming earnings report will provide valuable insights into the company's performance and the effectiveness of its strategies to address the Alaris infusion pump recall. Investors and financial professionals should closely monitor the release to gauge the company's ability to navigate challenges and capitalize on growth opportunities.

References:
[1] https://www.barchart.com/story/news/33641764/earnings-preview-what-to-expect-from-becton-dickinson-and-company-s-report
[2] https://www.marketbeat.com/instant-alerts/filing-becton-dickinson-and-company-nysebdx-shares-bought-by-john-g-ullman-associates-inc-2025-07-25/